IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimerâs disease in the United States and Colombia.
The companyâs lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimerâs.
Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimerâs disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers.
The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023.
IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
